Evolving systemic management of urothelial cancers
Tan W, Tan M, Alhalabi O, Campbell M, Kamat A, Gao J. Evolving systemic management of urothelial cancers. Current Opinion In Oncology 2023, 35: 186-199. PMID: 36966497, DOI: 10.1097/cco.0000000000000942.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Transitional CellHumansImmune Checkpoint InhibitorsImmunoconjugatesImmunotherapyUrinary Bladder NeoplasmsConceptsPlatinum-based chemotherapyInvasive bladder cancerBladder cancerAntibody-drug conjugatesFibroblast growth factor receptorCheckpoint inhibitorsUrothelial carcinomaProgrammed cell death-ligand 1 inhibitorsLocalized muscle invasive bladder cancerImprove bladder cancer outcomesNonmuscle invasive bladder cancerTraditional platinum-based chemotherapyProgrammed cell death 1Management of urothelial carcinomaMuscle invasive bladder cancerImmune checkpoint inhibitorsCell death 1Third-line optionBladder cancer outcomesResponse to therapyGrowth factor receptorFood and Drug AdministrationDeath-1Second-lineSystemic treatment